Your browser doesn't support javascript.
Sotrovimab Lowers the Risk of COVID-19 Related Hospitalization or Death in a Large Population Cohort in the United Arab Emirates.
Saheb Sharif-Askari, Fatemeh; Ali Hussain Alsayed, Hawra; Tleyjeh, Imad; Saheb Sharif-Askari, Narjes; Al Sayed Hussain, Ali; Saddik, Basema; Hamid, Qutayba; Halwani, Rabih.
  • Saheb Sharif-Askari F; Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
  • Ali Hussain Alsayed H; Pharmacy, Dubai Health Authority, Dubai, United Arab Emirates.
  • Tleyjeh I; Infectious Diseases Section, Department of Medical Specialties, King Fahad Medical City, Riyadh, Saudi Arabia.
  • Saheb Sharif-Askari N; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
  • Al Sayed Hussain A; Division of Infectious Diseases, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
  • Saddik B; Division of Epidemiology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
  • Hamid Q; Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
  • Halwani R; Pharmacy, Dubai Health Authority, Dubai, United Arab Emirates.
Clin Pharmacol Ther ; 112(6): 1214-1223, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-1913781
ABSTRACT
Sotrovimab, an anti-severe acute respiratory syndrome-coronavirus 2 monoclonal antibody is being utilized to prevent progression of coronavirus disease 2019 (COVID-19). Therefore, to understand its benefits, we have conducted a retrospective analysis of all non-hospitalized patients with symptomatic COVID-19 who received a single infusion of sotrovimab and/or oral favipiravir at any Dubai COVID-19 related healthcare center between July 1, 2021, and October 31, 2021. The main outcome was to evaluate the risk of hospitalization for patients with COVID-19 or all-cause death within 28 days of treatment initiation. In this analysis, which included 10,882 patients (1,135 in the sotrovimab group, 2,653 in the sotrovimab/favipiravir group, and 7,094 in the favipiravir group), sotrovimab or sotrovimab/favipiravir reduced the risk of hospitalization (13 patients (1.5%) in the sotrovimab group and 71 patients (2.9%) in the sotrovimab/favipiravir group vs. 251 patients (4%) in the favipiravir group; hazard ratio (HR) for sotrovimab 0.16, 95% confidence interval (CI) 0.09-0.28, P < 0.001; and for sotrovimab/favipiravir, HR 0.42, 95% CI 0.32-0.56, P < 0.001), or death by day 28 from the start of treatment (no death in the sotrovimab group and 2 deaths in the the sotrovimab/favipiravir group vs. 10 deaths in the favipiravir group; odds ratio 0.18, 95% CI 0.04 to 0.81, P = 026). Safety was assessed in all the 3,788 patients in the sotrovimab and sotrovimab/favipiravir groups, and the reported adverse events were by 34 patients (<1%). In conclusion, sotrovimab was found to reduce the risk of progression of COVID-19 when administrated early to non-hospitalized patients with symptomatic COVID-19. No safety concern was detected.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Asia Language: English Journal: Clin Pharmacol Ther Year: 2022 Document Type: Article Affiliation country: Cpt.2700

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Asia Language: English Journal: Clin Pharmacol Ther Year: 2022 Document Type: Article Affiliation country: Cpt.2700